Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.75 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.75 |
| ▸ | HPGD | P15428 | 2/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.75 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.75 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.75 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.75 |
| ▸ | BLM | P54132 | 1/20 | 0.75 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.75 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.71 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | TP53 | P04637 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | MTOR | P42345 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29371389 | 0.87 | CYP1A2 (1.00) | CYP1A2CYP3A4CYP2D6HPGDALDH1A1 | |
| SCHEMBL5889449 | 0.87 | CYP1A2 (1.00) | CYP1A2CYP3A4CYP2D6HPGDALDH1A1 | |
| SCHEMBL1155582 | 0.87 | CYP1A2 (1.00) | CYP1A2CYP3A4CYP2D6HPGDALDH1A1 | |
| SCHEMBL5088067 | 0.87 | CYP1A2 (1.00) | CYP1A2CYP3A4CYP2D6HPGDALDH1A1 | |
| SCHEMBL8373082 | 0.87 | CYP1A2 (1.00) | CYP1A2CYP3A4CYP2D6HPGDALDH1A1 | |
| SCHEMBL679954 | 0.87 | CYP1A2 (1.00) | CYP1A2CYP3A4CYP2D6HPGDALDH1A1 | |
| Nonivamide SCHEMBL81939 | 0.87 | CYP1A2 (1.00) | CYP1A2CYP3A4CYP2D6HPGDALDH1A1 | |
| SCHEMBL2400979 | 0.87 | CYP1A2 (1.00) | CYP1A2CYP3A4CYP2D6HPGDALDH1A1 | |
| SCHEMBL1155739 | 0.87 | CYP1A2 (1.00) | CYP1A2CYP3A4CYP2D6HPGDALDH1A1 | |
| Nonivamide SCHEMBL29425552 | 0.87 | CYP1A2 (1.00) | CYP1A2CYP3A4CYP2D6HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220227774-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | ASANA BIOSCIENCES, LLC | 2022-07-21 | — | — | US | disclosed |
| US-11339169-B2 | P2X3 and/or P2X2/3 compounds and methods | ASANA BIOSCIENCES, LLC (US) | 2022-05-24 | — | — | US | disclosed |
| EP-3083619-B1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | ASANA BIOSCIENCES LLC (US) | 2021-11-03 | — | — | EP | disclosed |
| EP-3363437-B1 | AMINOINDANE COMPOUNDS AND USE THEREOF IN TREATING PAIN | ENDO PHARMACEUTICALS SOLUTIONS (US) | 2021-07-28 | — | — | EP | disclosed |
| US-20200190096-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | ASANA BIOSCIENCES, LLC | 2020-06-18 | — | — | US | disclosed |
| US-10611768-B2 | P2X3 and/or P2X2/3 compounds and methods | ASANA BIOSCIENCES, LLC (US) | 2020-04-07 | — | — | US | disclosed |
| US-10590127-B2 | P2X3 and/or P2X2/3 compounds and methods | ASANA BIOSCIENCES, LLC (US) | 2020-03-17 | — | — | US | disclosed |
| US-10544145-B2 | P2X3 and/or P2X2/3 compounds and methods | ASANA BIOSCIENCES, LLC (US) | 2020-01-28 | — | — | US | disclosed |
| EP-3528813-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | Asana BioSciences, LLC (US) | 2019-08-28 | — | — | EP | disclosed |
| US-20190248789-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | ABS DEVELOPMENT 1, INC. | 2019-08-15 | — | — | US | disclosed |
| US-20140213552-A1 | CYCLOHEXYLAMINES | ENDO PHARMACEUTICALS INC. (US) | 2014-07-31 | — | — | US | disclosed |
| WO-2014028675-A1 | USE OF AMINOINDANE COMPOUNDS IN TREATING OVERACTIVE BLADDER AND INTERSTITIAL CYSTITIS | ENDO PHARMACEUTICALS INC. (US) | 2014-02-20 | — | — | WO | disclosed |
| EP-2675787-A1 | AMINOINDANE COMPOUNDS AND USE THEREOF IN TREATING PAIN | Endo Pharmaceuticals Inc. (US) | 2013-12-25 | — | — | EP | disclosed |
| WO-2013063127-A1 | CYCLOHEXYLAMINES | ENDO PHARMACEUTICALS INC. (US) | 2013-05-02 | — | — | WO | disclosed |
| US-20130101667-A1 | Cyclohexylamines | ENDO PHARMACEUTICALS, INC. (US) | 2013-04-25 | — | — | US | disclosed |
| WO-2012112969-A1 | AMINOINDANE COMPOUNDS AND USE THEREOF IN TREATING PAIN | ENDO PHARMACEUTICALS INC. (US) | 2012-08-23 | — | — | WO | disclosed |
| US-20120214809-A1 | Aminoindane Compounds and Use Thereof in Treating Pain | Libertas Bio, Inc. | 2012-08-23 | — | — | US | disclosed |
| US-20110086818-A1 | METHODS, COMPOSITIONS, AND KITS FOR TREATING PAIN AND PRURITUS | PRESIDENTS AND FELLOWS OF HARVARD COLLEGE (US) | 2011-04-14 | — | — | US | disclosed |
| EP-2271329-A2 | METHODS, COMPOSITIONS, AND KITS FOR TREATING PAIN AND PRURITIS | President and Fellows of Harvard College (US) | 2011-01-12 | — | — | EP | disclosed |
| WO-2009114139-A2 | METHODS, COMPOSITIONS, AND KITS FOR TREATING PAIN AND PRURITIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2009-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10544145-B2 | P2X3 and/or P2X2/3 compounds and methods | P2RX3, P2RX2, P2RX1 | CYP1A2 1920/4885CYP3A4 2422/4885CYP2D6 1713/4885 |
| US-20220227774-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | P2RX3, P2RX6, P2RX2 | CYP1A2 1779/4885CYP3A4 2455/4885CYP2D6 1132/4885 |
| US-11339169-B2 | P2X3 and/or P2X2/3 compounds and methods | P2RX3, P2RX6, P2RX2 | CYP1A2 1779/4885CYP3A4 2455/4885CYP2D6 1132/4885 |
| US-20120214809-A1 | Aminoindane Compounds and Use Thereof in Treating Pain | TRPA1, TRPV1, TRPV2 | CYP1A2 1238/4885CYP3A4 3017/4885CYP2D6 1509/4885 |
| US-20200190096-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | P2RX3, P2RX6, P2RX2 | CYP1A2 1779/4885CYP3A4 2455/4885CYP2D6 1132/4885 |
| US-10590127-B2 | P2X3 and/or P2X2/3 compounds and methods | P2RX3, P2RX2, P2RX1 | CYP1A2 1695/4885CYP3A4 2035/4885CYP2D6 1635/4885 |
| US-20110086818-A1 | METHODS, COMPOSITIONS, AND KITS FOR TREATING PAIN AND PRURITUS | TRPV1, OPRL1, ITCH | CYP1A2 4784/4885CYP3A4 4788/4885CYP2D6 4656/4885 |
| US-10611768-B2 | P2X3 and/or P2X2/3 compounds and methods | P2RX3, P2RX6, P2RX2 | CYP1A2 1779/4885CYP3A4 2455/4885CYP2D6 1132/4885 |
| US-20140213552-A1 | CYCLOHEXYLAMINES | TRPV1, TRPA1, OPRL1 | CYP1A2 1217/4885CYP3A4 2668/4885CYP2D6 1398/4885 |
| US-20130101667-A1 | Cyclohexylamines | TRPV1, TRPA1, OPRL1 | CYP1A2 1217/4885CYP3A4 2668/4885CYP2D6 1398/4885 |
| US-20190248789-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | P2RX3, P2RX2, P2RX1 | CYP1A2 1920/4885CYP3A4 2422/4885CYP2D6 1713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.